In George Medicines’ Phase III trial among 1,385 patients in Australia, Czech Republic, New Zealand, Poland, Sri Lanka, UK and the US, standard- and half-dose forms of GMRx2 were tested against dual combinations of its component drugs. GMRx2 significantly reduced blood pressure and improved control rates vs dual therapy, with good tolerability and no increase …
Among Black African adults with uncontrolled hypertension, a low-dose triple-pill protocol achieved better blood pressure lowering and control with good tolerability compared with the standard-care protocol, according to the VERONICA (deliVERy of Optimal blood pressure coNtrol in afrICA) trial – the first trial to evaluate a low-dose triple combination pill as initial or early therapy …
In George Medicines’ placebo-controlled Phase III trial of GMRx2, among patients in Australia, Nigeria, Sri Lanka, UK and the US, comparing half- and quarter-doses of GMRx2 against a placebo pill, GMRx2 significantly improved home- and clinic-measured blood pressure and control rates, in both half- and quarter-doses. Tolerability to GMRx2 was good, with no increase in withdrawal …
Early identification of stroke type could be key to harnessing the benefits of very early in-ambulance blood pressure-lowering treatment in patients with suspected acute stroke, according to a study led by researchers from The George Institute for Global Health. The study shows clear benefits from administering early blood pressure-lowering treatment to patients with intracerebral haemorrhage …
George Medicines’ Chief Medical Officer, Professor Anthony Rodgers, and steering committee members of the Company’s GMRx2 phase III trial programme examine the rationale for the single-pill, once-daily, triple combination of best-in-class medicines for the treatment of hypertension, including first-line therapy. Low-dose triple combinations have shown great promise to lead to a step change in hypertension …
As part of ongoing initiatives for countries to strengthen universal health care, the WHO, together with ministries of health and other partners, has demonstrated the feasibility of using hypertension programmes in primary care as a pathfinder for universal health coverage. This report identifies a list of research priorities for hypertension care, intended to provide a …